

**REMARKS*****Status of the claims***

Claims 1-44, 47 and 49-53 were pending in the present application. Claims 45, 46 and 48 were objected to and withdrawn from consideration by the Examiner. By virtue of this response, claims 1, and 20-53 have been cancelled, claims 2, 18, and 19 have been amended, and new claims 54-57 have been added. Accordingly, claims 2-19 and 54-57 are currently under consideration. Allowance of the pending claims is respectfully requested.

With respect to all amendments and cancelled claims, Applicant has not dedicated or abandoned any unclaimed subject matter. Applicant reserves the right to pursue prosecution of any presently excluded claim embodiments in future continuation and/or divisional applications.

***Claim amendments***

The amendments to claims 2, 18, and 19, as well as new claims 54-57, are fully supported by the original application.

Claim 2 is amended to read as an independent claim in light of the cancellation of claim 1. Claim 2 has also been amended to recite “wherein the at least one difference or at least one similarity is displayed on a heat map or targeting chart.” Support for this amendment is found, e.g., at page 37, line 4, to page 39, line 30, of the application as filed.

Claims 18 and 19 are amended to correct antecedent basis.

New claims 54 and 55 find support, e.g., at page 37, line 4, to page 39, line 30, of the application as filed. New claim 56 finds support, e.g., at p. 37, lines 25-27, of the application. New claim 57 finds support in original claim 48.

No new matter is added by the amendment to the claims.

***Objection to claims 45, 46, and 48***

Claims 45, 46 and 48 were objected to and withdrawn from consideration by the Examiner as depending on a non-existent claim 60. Applicants have now cancelled claims 45, 46, and 48.

***Restriction requirement/election of species***

Applicant hereby elects Group I (claims 2-19, as amended, and new claims 54-57), without traverse, for continued examination.

In addition, Applicant elects the following five species, without traverse:

Category #1: 5,8,11-eicosatrienoic acid and 5,8,11,14,17-eicosapentaenoic acid, upon which claims 2-19 and 54-57 are readable;

Category #2: 18:2n6, upon which claims 2-7, 9-19, and 54-57 are readable;

Category #3: 5-cholesten-3b-ol, upon which claims 2-6, 8-19, and 54-57 are readable;

Category #4: cardiolipin, upon which claims 2-7, 9-19, and 54-57 are readable;  
and

Category #5: dipentadecaenoyl phosphatidylethanolamine, upon which claims 2-7, 9-10, 12-19, and 54-57 are readable.

Applicant expressly reserves Applicant's right under 35 U.S.C. § 121 to file a divisional application directed to the non-elected subject matter during the pendency of this application, or an application claiming priority from this application.

Applicant requests examination of the elected subject matter on the merits.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicant petitions for any required relief including extensions of time and authorize the Commissioner to charge the cost of

such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 475512000100. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: September 29, 2006

Respectfully submitted,

By 

Alicia J. Hager

Registration No.: 44,140

MORRISON & FOERSTER LLP

755 Page Mill Road

Palo Alto, California 94304-1018

(650) 813-4296